Abstract 264: Circulating Tnni3k Levels Are Useful Diagnosis Biomarker for Acute Ischemic Myocardial Diseases

Our recent data showed that TNNI3K, a MAP kinase specifically expressed in cardiac muscles and interacted with cardiac troponin I, TNNI3K high-expression enhanced cardiac performance, attenuated ischemia-induced ventricular remodeling in mice with myocardial infarction, and protected the myocardium from ischemic injury. In the present study, availability of circulating TNNI3K level was investigated using anti-TNNI3K polyclonal antibodies with ELISA, in patients diagnosed as AMI, chronic heart failure and acute renal failure; and in healthy volunteers groups. Data shown that circulating TNNI3K levels were significantly higher in AMI when compared with other two groups (p<0.001), indicating that measurement of circulating TNNI3K is a novel and useful diagnosing tool for AMI. Then, we made an anti-TNNI3K monoclonal antibody to investigate whether circulating TNNI3K levels play the same role for diagnosis of ischemic myocardial diseases, the availability of serum TNNI3K level was investigated with anti-TNNI3K...